Abstract Search

ea0070ep197 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

Cardenas Jersy , Sanchez Gomez Nancy , Miguel Sierra Poyatos Roberto , Luiza Luca Bogdana , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Silva Rodriguez Maria Jesus , Ortega Juaristi Maite , Meneses González Diego , De Los Angeles Gonzalo Redondo Maria , Galdon Sanz–Pastor Alba , Ruiz Sanchez Jorge , De La Paz Gómez Montes María , Cruces Vega Cristina , Vazquez Martinez Clotilde

Objectives: Semaglutide was approved for the treatment of T2DM patients with a body mass index (BMI) > 30kg/m2 by the Spanish National Health Service in May 2019. We evaluate clinical outcomes of patients on previous treatment with any another GLP1–RA that switch to Semaglutide.Material and Methods: Retrospective analysis. Sixty–five T2DM patients were included. Demographic data, anthropometric, systolic blood pressure (SBP), d...

0 shares

Endocrine Abstracts

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

BiosciAbstracts